As of Feb 27
| -1.89 / -0.87%|
The 20 analysts offering 12-month price forecasts for Pharmacyclics Inc have a median target of 185.50, with a high estimate of 253.00 and a low estimate of 128.00. The median estimate represents a -14.09% decrease from the last price of 215.93.
The current consensus among 22 polled investment analysts is to Hold stock in Pharmacyclics Inc. This rating has held steady since February, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.